Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
Xiao Shen,Jin-Xing Zhang,Jin Liu,Sheng Liu,Hai-Bin Shi,Yuan Cheng,Qing-Qiao Zhang,Guo-Wen Yin,Qing-Quan Zu
DOI: https://doi.org/10.2147/jhc.s478604
2024-10-22
Journal of Hepatocellular Carcinoma
Abstract:Xiao Shen, 1 Jin-Xing Zhang, 1 Jin Liu, 2 Sheng Liu, 1 Hai-Bin Shi, 1 Yuan Cheng, 3 Qing-Qiao Zhang, 4 Guo-Wen Yin, 5 Qing-Quan Zu 1 1 Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China; 2 Department of Clinical Medicine Research Institution, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China; 3 Department of Medical Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210002, People's Republic of China; 4 Department of Interventional Radiology and Vascular Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, People's Republic of China; 5 Department of Interventional Radiology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, People's Republic of China Correspondence: Qing-Quan Zu, Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, 210029, People's Republic of China, Tel +86-13913807470, Fax +86-25-83724440, Email Purpose: Transarterial chemoembolization (TACE), when used in combination with immunotherapy and antiangiogenic therapy, has been shown to have synergistic anticancer effects. The aim of this study was to further assess the efficacy and safety of TACE combined with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC) in the real world. Methods: Between August 2021 and September 2023, clinical information was collected from consecutive HCC patients who received treatment via TACE-Atezo/Bev at four tertiary institutions. This study evaluated the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) as outcomes. Predictors for OS and PFS were also analyzed. Treatment-related adverse events (TRAEs) were recorded and assessed. Results: Ninety-two patients were enrolled in this study, with a median follow-up duration of 14.1 months. The ORRs based on the modified Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria were 54.3% and 41.3%, respectively. The median OS and PFS of the patients were 15.9 months [95% confidence interval (CI), 14.5– 17.2 months] and 9.1 months (95% CI, 7.4– 10.8 months), respectively. Multivariate analyses revealed that the Eastern Cooperative Oncology Group score and neutrophil‒lymphocyte ratio were independent risk factors for OS, whereas tumor size and extrahepatic metastasis were independent risk factors for PFS. Grade 3/4 TRAEs occurred in 16.3% (15/92) of the patients and were controlled conservatively. Conclusion: The combination of Atezo/Bev with TACE demonstrated acceptable synergistic therapeutic effects and manageable safety profiles in patients with unresectable HCC. Keywords: atezolizumab, bevacizumab, efficacy, hepatocellular carcinoma, transarterial chemoembolization Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer-related death worldwide. 1 The majority of patients are often diagnosed at an intermediate or advanced stage, which restricts treatment options and results in a dismal prognosis. 2,3 Systemic therapies, including molecular therapies and immunotherapies, have transformed the treatment of unresectable HCC (uHCC), with the support of robust clinical trials. 4 The IMbrave 150 trial, the most representative study, demonstrated that atezolizumab plus bevacizumab (Atezo/Bev) was superior to sorafenib for patients with uHCC. 5 Consequently, Atezo/Bev was approved for first‐line systemic therapy according to the American Society of Clinical Oncology guidelines. 6 Many studies have been conducted on the combination of antiangiogenic agents (including bevacizumab) with transarterial chemoembolization (TACE) to counteract TACE-induced vascular endothelial growth factor (VEGF) release, and encouraging results have been obtained. 7 TACE, which induces antigen release and the expression of programmed cell death 1 ligand 1 (PD-L1), promotes the formation of an immunosuppressive microenvironment to enhance the response to PD-L1 inhibitors. 8 Driven by theory, there is growing interest in combining tyrosine kinase inhibitors and PD-1 inhibitor therapies with TACE for treating HCC, which has shown encouraging therapeutic effects and tolerable safety profiles. 9,10 Recently, in a Phase III trial of TACE combined with durvalumab with bevacizumab, EMERALD-1 the exciting primary research endpoi -Abstract Truncated-
oncology